Antibodies to lipoproteins and apolipoproteins and methods of use thereof
First Claim
1. A method for determining the relative ratio of at least two different lipoproteins or apolipoproteins in a biological sample comprising:
- immersing into the sample a solid phase material having separately immobilized thereon at least first and second antibody molecules, wherein the antibody molecules are selected from the group consisting of monoclonal antibodies, recombinant antibodies and antigen-binding antibody fragments thereof, wherein the antibody molecules are immunoreactive with at least two different lipoproteins, wherein the first and second antibodies bind to different stable, conformation independent epitopes that are uninfluenced by the lipid content of the lipoprotein, protein component of the lipoprotein or lipid associated with the specific lipoprotein, wherein the lipoproteins are selected from the group consisting of LDL, HDL and VLDL;
allowing the antibody molecules time to bind to the LDL, HDL, VLDL or apolipoproteins in the sample;
removing the solid phase material containing the immobilized antibody molecules;
determining the amount of lipoprotein or apolipoproteins bound by the immobilizedantibody molecules, andcomparing the amount bound which is specific for LDL, HDL, VLDL or each apolipoprotein in order to calculate the relative amounts of LDL, HDL, VLDL or apolipoproteins.
0 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods using antibodies which are immunoreactive with specific apolipoproteins to determine the concentrations of lipoproteins such as HDL and LDL, and/or apolipoproteins in human blood, serum or plasma sample, are described. Monoclonal antibodies (MAbs) are described that specifically bind to epitopes present in apolipoproteins and lipoproteins, enabling rapid and reliable determinations of levels of specific blood lipoprotein and/or apolipoprotein levels, including Apo B-100, Apo A-I, Apo A-II, Apo C-III, and Apo E, and thereby determination of relative ratios of HDL and LDL and LpaI and LpaII. In a preferred embodiment, the compositions are strips of a solid phase material coated with one or more of the antibodies and are referred to herein as “dipsticks”. The dipsticks specifically bind a lipoprotein or apolipoprotein when dipped into a protein sample. The amount of lipid associated with a bound lipoprotein or the amount of apolipoprotein bound on the dipstick is quantitated using an appropriate method, for example, by staining with a lipid stain or reaction with a second labelled antibody. The intensity of the stain on the dipstick is proportional to the concentration of the lipoprotein lipid or apolipoprotein circulating in the blood and can be quantitated by comparison with standards containing known amounts of lipid.
-
Citations
19 Claims
-
1. A method for determining the relative ratio of at least two different lipoproteins or apolipoproteins in a biological sample comprising:
-
immersing into the sample a solid phase material having separately immobilized thereon at least first and second antibody molecules, wherein the antibody molecules are selected from the group consisting of monoclonal antibodies, recombinant antibodies and antigen-binding antibody fragments thereof, wherein the antibody molecules are immunoreactive with at least two different lipoproteins, wherein the first and second antibodies bind to different stable, conformation independent epitopes that are uninfluenced by the lipid content of the lipoprotein, protein component of the lipoprotein or lipid associated with the specific lipoprotein, wherein the lipoproteins are selected from the group consisting of LDL, HDL and VLDL; allowing the antibody molecules time to bind to the LDL, HDL, VLDL or apolipoproteins in the sample; removing the solid phase material containing the immobilized antibody molecules; determining the amount of lipoprotein or apolipoproteins bound by the immobilizedantibody molecules, and comparing the amount bound which is specific for LDL, HDL, VLDL or each apolipoprotein in order to calculate the relative amounts of LDL, HDL, VLDL or apolipoproteins. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method for determining the relative ratio of LDL to HDL in a biological sample comprising
(a) determining the amount of LDL in the sample by adding to the sample monoclonal antibody molecules immunoreactive with low density lipoprotein and not cross-reactive with high density lipoprotein and determining the amount of low density lipoprotein; -
(b) determining the amount of HLD in the sample by adding to the sample monoclonal antibody molecules immunoreactive with high density lipoprotein and not cross-reactive with low density lipoprotein and determining the amount of high density lipoprotein; and (c) determining the ratio of the amount of low density lipoprotein with the amount of high density lipoprotein, wherein at least one of the monoclonal antibodies to LDL and HDL bind a stable, conformation independent epitope that is uninfluenced by the lipid content of the lipoprotein, the protein component of the lipoprotein or lipid associated with the specific lipoprotein.
-
-
13. A method for determining the relative ratio of VLDL to HDL comprising
(a) determining the amount of VLDL in the sample by determining the amount of Apo E present in the VLDL in the sample by providing Pan B antibody which is characterized by an equal binding and high affinity for all Apo B-containing lipoproteins in human plasma, providing monoclonal antibody which specifically binds to Apo E associated with VLDL, contacting the antibodies reactive with Apo E associated with VLDL with the biological sample to form complexes between the anti-ApoE antibodies and Apo E containing particles, contacting Pan B antibody with the biological sample containing the complexes between the anti-ApoE antibodies and ApoE containing particles to form complexes of anti-ApoB-anti-ApoE-ApoE containing particles, and determining the amount of Apo E in the complexes of anti-ApoB-anti-ApoE-ApoE containing particles, which is the Apo E present in VLDL in the sample; -
(b) removing the complexes of anti-ApoB-anti-ApoE-ApoE containing particles, either by binding of the anti-Apo E antibodies to an immobilized surface or centrifugation of sample to remove the complexes of anti-ApoB-anti-ApoE-ApoE containing particles; and (c) determining the amount of HDL in the sample by determining the amount of Apo E present in the HDL in the sample by providing Apo A-I monoclonal antibody immunoreactive specifically with Apo A-I, contacting antibodies reactive with Apo E in HDL particles with the biological sample to form complexes between the anti-ApoE antibodies and Apo E containing particles, contacting the Apo A-I monoclonal antibody with the biological sample to form complexes of the anti-ApoE antibodies-ApoE containing particles-anti-ApoA-I, determining the amount of Apo E present in HDL in the complexes of the anti-ApoE antibodies-ApoE containing particles-anti-Apo A-I in the sample, and determining the ratio of Apo E present in VLDL in the sample and Apo E present in HDL in the sample which is the ratio of VLDL to HDL, wherein at least one of the monoclonal antibodies bind to a stable, conformation independent epitope that is uninfluenced by the lipid content of the lipoprotein, protein component of the lipoprotein or lipid associated with a specific lipoprotein selected from the group consisting of Apo B, Apo AI, and Apo E.
-
-
14. A kit for determining the relative ratio of VLDL to HDL comprising
Pan B antibody which is characterized by an equal binding and high affinity for all Apo B-containing lipoproteins in human plasma, monoclonal or recombinant antibody specifically immunoreactive with Apo C-III, and monoclonal or recombinant Apo A-I antibody specifically immunoreactive with Apo A-I, wherein at least one of the monoclonal or recombinant antibodies specifically bind to a stable, conformation independent epitope of a lipoprotein including Apo C-III or Apo A-I that is uninfluenced by the lipid content of the lipoprotein, protein component thereof or lipid associated with a specific lipoprotein selected from the group consisting of Apo AI, and Apo CIII.
-
16. A kit for determining the relative ratio of VLDL to HDL comprising
Pan B antibody which is characterized by an equal binding and high affinity for all Apo B-containing lipoproteins in human plasma, monoclonal antibody which binds to Apo E associated with VLDL, monoclonal Apo A-I antibody specifically immunoreactive with Apo A-I, and monoclonal antibody which binds to Apo E in HDL, wherein at least one of the antibodies binds to a stable, conformation independent epitope of a lipoprotein containing Apo E or Apo A-I that is uninfluenced by the lipid content of the lipoprotein, protein component of the lipoprotein or lipid associated with a specific lipoprotein.
-
18. A kit for determining the relative ratio of LPA-I and LPA-II lipoprotein particles comprising
monoclonal or recombinant Apo-A-I antibody specifically immunoreactive with Apo A-I lipoproteins in human plasma; - and
monoclonal or recombinant Apo A-II antibody specifically immunoreactive with Apo A-II, wherein the anti-Apo A-I or anti-Apo A-II monoclonal or recombinant antibody molecules are selected from the group consisting of monoclonal antibodies, recombinant antibodies, and antigen-binding antibody fragments thereof that specifically bind to a stable, conformation independent epitope of a lipoprotein containing Apo A-I or Apo A-II which is uninfluenced by the lipid content of the lipoprotein, protein component of the lipoprotein, or lipid associated with a specific lipoprotein. - View Dependent Claims (19)
- and
Specification